Trial 4P-15-1


A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (Provenge®) for patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Tanya Dorff, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Aleksei Belousov, Coordinator, Lagrimas Ilagan, D.M., Honorina Enright, D.M., Charis Barg, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.